• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

泊洛妥珠单抗治疗复发/难治性非霍奇金淋巴瘤患者的概况：关于新出现临床数据的简要报告

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.

作者信息

Sawalha Yazeed, Maddocks Kami

机构信息

Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

出版信息

Onco Targets Ther. 2020 Jun 8;13:5123-5133. doi: 10.2147/OTT.S219449. eCollection 2020.

DOI:10.2147/OTT.S219449
PMID:32606733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7293382/
Abstract

ABSTRACT

Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma.

METHODS

We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. We also reviewed the package insert and available abstracts and posters presented at national and international meetings.

摘要

摘要

泊洛妥珠单抗是一种与单甲基奥瑞他汀E偶联的抗CD79b抗体，已在滤泡性和弥漫性大B细胞淋巴瘤（DLBCL）中显示出显著的临床活性，目前已获美国食品药品监督管理局（FDA）批准，可与苯达莫司汀和利妥昔单抗联合用于复发/难治性DLBCL患者。这篇综述文章总结了泊洛妥珠单抗的临床试验数据，并讨论了其在B细胞非霍奇金淋巴瘤患者治疗中的当前作用和未来方向。

方法

我们在PubMed和谷歌学术上进行了从数据库建立到2020年1月的文献检索，使用了以下检索词：泊洛妥珠单抗和CD79。我们还查阅了药品说明书以及在国内和国际会议上展示的可用摘要和海报。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e04a/7293382/f1ca230da4d5/OTT-13-5123-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e04a/7293382/f1ca230da4d5/OTT-13-5123-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e04a/7293382/f1ca230da4d5/OTT-13-5123-g0001.jpg

相似文献

1
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.泊洛妥珠单抗治疗复发/难治性非霍奇金淋巴瘤患者的概况：关于新出现临床数据的简要报告
Onco Targets Ther. 2020 Jun 8;13:5123-5133. doi: 10.2147/OTT.S219449. eCollection 2020.
2
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.抗 CD79B 抗体药物偶联物 polatuzumab vedotin 在复发或难治性 B 细胞非霍奇金淋巴瘤和慢性淋巴细胞白血病中的安全性和活性：一项 1 期研究。
Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.
3
Polatuzumab Vedotin: First Global Approval.泊洛妥珠单抗结合药物：全球首次获批
Drugs. 2019 Sep;79(13):1467-1475. doi: 10.1007/s40265-019-01175-0.
4
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.泊洛妥珠单抗维达替尼治疗弥漫性大B细胞淋巴瘤患者的疗效评估。
Expert Rev Hematol. 2020 Sep;13(9):933-942. doi: 10.1080/17474086.2020.1795828. Epub 2020 Aug 10.
5
Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.波拉珠单抗维泊妥珠单抗：一种研究性抗 CD79b 抗体药物偶联物，用于治疗弥漫性大 B 细胞淋巴瘤。
Expert Opin Investig Drugs. 2020 Oct;29(10):1079-1088. doi: 10.1080/13543784.2020.1800638. Epub 2020 Aug 12.
6
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.泊洛妥珠单抗联合化疗治疗复发或难治性弥漫大 B 细胞淋巴瘤成人患者。
Expert Opin Biol Ther. 2021 Jul;21(7):831-839. doi: 10.1080/14712598.2020.1777979. Epub 2020 Jun 15.
7
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.泊洛妥珠单抗联合苯达莫司汀及利妥昔单抗用于治疗复发或难治性弥漫性大B细胞淋巴瘤。
Drugs Today (Barc). 2020 Apr;56(4):287-294. doi: 10.1358/dot.2020.56.4.3127026.
8
Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗：在弥漫性大B细胞淋巴瘤患者治疗中的当前作用及未来应用
Clin Hematol Int. 2021 Mar 13;3(1):21-26. doi: 10.2991/chi.k.210305.001. eCollection 2021 Mar.
9
Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.在复发或难治性 B 细胞非霍奇金淋巴瘤患者中，帕洛昔单抗维地滨的免疫原性综合总结。
Front Immunol. 2023 Mar 29;14:1119510. doi: 10.3389/fimmu.2023.1119510. eCollection 2023.
10
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.泊洛妥珠单抗，一种用于治疗复发/难治性弥漫性大B细胞淋巴瘤的抗CD79b抗体药物偶联物。
Future Oncol. 2021 Jan;17(2):127-135. doi: 10.2217/fon-2020-0675. Epub 2020 Sep 21.

引用本文的文献

1
The Efficacy of Polatuzumab Vedotin Targeting CD79B in the Treatment of Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.靶向CD79B的泊洛妥珠单抗治疗非霍奇金淋巴瘤的疗效：一项系统评价和Meta分析
Int J Mol Sci. 2025 Jul 16;26(14):6836. doi: 10.3390/ijms26146836.
2
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.复发/难治性伴有MYC易位的弥漫性大B细胞淋巴瘤采用泊洛妥珠单抗、苯达莫司汀和利妥昔单抗治疗的临床结局较差。
J Clin Exp Hematop. 2023 Sep 28;63(3):201-204. doi: 10.3960/jslrt.23017. Epub 2023 Jul 28.
3

本文引用的文献

1
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.波拉珠单抗维地布用于复发/难治弥漫性大 B 细胞淋巴瘤。
J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6.
2
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.奥妥珠单抗联合来那度胺治疗复发或难治性滤泡性B细胞淋巴瘤（GALEN）：一项多中心、单臂、2期研究。
Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8.
3
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?
治疗B细胞恶性肿瘤新型药物的现状：接下来会有什么进展？
Cancers (Basel). 2022 Dec 7;14(24):6026. doi: 10.3390/cancers14246026.
4
Delivery of Drugs into Cancer Cells Using Antibody-Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect.基于受体介导的内吞作用以及增强的渗透与滞留效应，利用抗体-药物偶联物将药物递送至癌细胞。
Antibodies (Basel). 2022 Dec 19;11(4):78. doi: 10.3390/antib11040078.
5
Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies.淋巴瘤的靶向治疗和细胞治疗：逃逸机制与创新策略
Front Oncol. 2022 Sep 12;12:948513. doi: 10.3389/fonc.2022.948513. eCollection 2022.
6
Immunotherapy in indolent Non-Hodgkin's Lymphoma.惰性非霍奇金淋巴瘤的免疫治疗
Leuk Res Rep. 2022 May 18;17:100325. doi: 10.1016/j.lrr.2022.100325. eCollection 2022.
7
Follicular lymphoma: updates for pathologists.滤泡性淋巴瘤：给病理学家的最新资讯
J Pathol Transl Med. 2022 Jan;56(1):1-15. doi: 10.4132/jptm.2021.09.29. Epub 2021 Dec 27.
8
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.泊洛妥珠单抗维泊妥珠单抗作为复发或难治性大B细胞淋巴瘤的挽救和桥接治疗。
Blood Adv. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155.
泊洛妥珠单抗联合免疫化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤患者的开放性、非随机、1b-2 期研究。
Lancet Oncol. 2019 Jul;20(7):998-1010. doi: 10.1016/S1470-2045(19)30091-9. Epub 2019 May 14.
4
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).复发或难治性非霍奇金淋巴瘤患者使用泊洛妥珠单抗或匹纳妥珠单抗联合利妥昔单抗治疗：一项2期随机研究（ROMULUS）的最终结果
Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29.
5
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.AUGMENT：来那度胺联合利妥昔单抗与安慰剂联合利妥昔单抗治疗复发或难治性惰性淋巴瘤的 III 期研究。
J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21.
6
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.利妥昔单抗联合来那度胺治疗晚期未经治疗的滤泡性淋巴瘤。
N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.
7
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤的遗传学与发病机制
N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.
8
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.奥滨尤妥珠单抗或利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗未经治弥漫性大 B 细胞淋巴瘤。
J Clin Oncol. 2017 Nov 1;35(31):3529-3537. doi: 10.1200/JCO.2017.73.3402. Epub 2017 Aug 10.
9
Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.抗CD22和抗CD79b抗体药物偶联物优先靶向增殖的B细胞。
Br J Pharmacol. 2017 Apr;174(8):628-640. doi: 10.1111/bph.13697. Epub 2017 Mar 6.
10
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.抗 CD79B 抗体药物偶联物 polatuzumab vedotin 在复发或难治性 B 细胞非霍奇金淋巴瘤和慢性淋巴细胞白血病中的安全性和活性：一项 1 期研究。
Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.